The sirolimus-eluting cypher select coronary stent for the treatment of bare-metal and drug-eluting stent restenosis

Insights from the e-select 64-71 (multicenter post-market surveillance) registry

Alexandre Abizaid, J. Ribamar Costa, Adrian Banning, Antonio L. Bartorelli, Vladimir Dzavik, Stephen Ellis, Runlin Gao, David R. Holmes, Muyng Ho Jeong, Victor Legrand, Franz Josef Neumann, Maria Nyakern, Amy Orlick, Christian Spaulding, Stephen Worthley, Philip M. Urban

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

This study sought to compare the 1-year safety and efficacy of Cypher Select or Cypher Select Plus (Cordis Corporation, Bridgewater, New Jersey) sirolimus-eluting stents (SES) with the treatment of bare-metal stents (BMS) and drug-eluting stent (DES) in-stent restenosis (ISR) in nonselected, real-world patients. There is paucity of consistent data on DES for the treatment of ISR, especially, DES ISR. The e-SELECT (Multicenter Post-Market Surveillance) registry is a Web-based, multicenter and international registry encompassing virtually all subsets of patients and lesions treated with at least 1 SES during the period from 2006 to 2008. We enrolled in this pre-specified subanalysis all patients with at least 1 clinically relevant BMS or DES ISR treated with SES. Primary endpoint was major adverse cardiac events and stent thrombosis rate at 1 year. Of 15,147 patients enrolled, 1,590 (10.5%) presented at least 1 ISR (BMS group, n = 1,235, DES group, n = 355). Patients with DES ISR had higher incidence of diabetes (39.4% vs. 26.9%, p <0.001), renal insufficiency (5.8% vs. 2.3%, p = 0.003), and prior coronary artery bypass graft (20.5% vs. 11.8%, p <0.001). At 1 year, death (1.4% for BMS vs. 2.1% for DES, p = 0.3) and myocardial infarction (2.4% for BMS and 3.3% for DES, p = 0.3) rates were similar, whereas ischemia-driven target lesion revascularization and definite/probable late stent thrombosis were higher in patients with DES ISR (6.9% vs. 3.1%, p = 0.003, and 1.8% vs. 0.5%, p = 0.04, respectively). Use of SES for either BMS or DES ISR treatment is safe and associated with low target lesion revascularization recurrence and no apparent safety concern.

Original languageEnglish
Pages (from-to)64-71
Number of pages8
JournalJACC: Cardiovascular Interventions
Volume5
Issue number1
DOIs
Publication statusPublished - Jan 2012

Fingerprint

Drug-Eluting Stents
Sirolimus
Stents
Registries
Metals
Therapeutics
Thrombosis
Safety

Keywords

  • in-stent restenosis
  • sirolimus-eluting stent(s)
  • target lesion revascularization

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

The sirolimus-eluting cypher select coronary stent for the treatment of bare-metal and drug-eluting stent restenosis : Insights from the e-select 64-71 (multicenter post-market surveillance) registry. / Abizaid, Alexandre; Costa, J. Ribamar; Banning, Adrian; Bartorelli, Antonio L.; Dzavik, Vladimir; Ellis, Stephen; Gao, Runlin; Holmes, David R.; Jeong, Muyng Ho; Legrand, Victor; Neumann, Franz Josef; Nyakern, Maria; Orlick, Amy; Spaulding, Christian; Worthley, Stephen; Urban, Philip M.

In: JACC: Cardiovascular Interventions, Vol. 5, No. 1, 01.2012, p. 64-71.

Research output: Contribution to journalArticle

Abizaid, A, Costa, JR, Banning, A, Bartorelli, AL, Dzavik, V, Ellis, S, Gao, R, Holmes, DR, Jeong, MH, Legrand, V, Neumann, FJ, Nyakern, M, Orlick, A, Spaulding, C, Worthley, S & Urban, PM 2012, 'The sirolimus-eluting cypher select coronary stent for the treatment of bare-metal and drug-eluting stent restenosis: Insights from the e-select 64-71 (multicenter post-market surveillance) registry', JACC: Cardiovascular Interventions, vol. 5, no. 1, pp. 64-71. https://doi.org/10.1016/j.jcin.2011.09.016
Abizaid, Alexandre ; Costa, J. Ribamar ; Banning, Adrian ; Bartorelli, Antonio L. ; Dzavik, Vladimir ; Ellis, Stephen ; Gao, Runlin ; Holmes, David R. ; Jeong, Muyng Ho ; Legrand, Victor ; Neumann, Franz Josef ; Nyakern, Maria ; Orlick, Amy ; Spaulding, Christian ; Worthley, Stephen ; Urban, Philip M. / The sirolimus-eluting cypher select coronary stent for the treatment of bare-metal and drug-eluting stent restenosis : Insights from the e-select 64-71 (multicenter post-market surveillance) registry. In: JACC: Cardiovascular Interventions. 2012 ; Vol. 5, No. 1. pp. 64-71.
@article{58847a42907041338ca6f3a02ea32493,
title = "The sirolimus-eluting cypher select coronary stent for the treatment of bare-metal and drug-eluting stent restenosis: Insights from the e-select 64-71 (multicenter post-market surveillance) registry",
abstract = "This study sought to compare the 1-year safety and efficacy of Cypher Select or Cypher Select Plus (Cordis Corporation, Bridgewater, New Jersey) sirolimus-eluting stents (SES) with the treatment of bare-metal stents (BMS) and drug-eluting stent (DES) in-stent restenosis (ISR) in nonselected, real-world patients. There is paucity of consistent data on DES for the treatment of ISR, especially, DES ISR. The e-SELECT (Multicenter Post-Market Surveillance) registry is a Web-based, multicenter and international registry encompassing virtually all subsets of patients and lesions treated with at least 1 SES during the period from 2006 to 2008. We enrolled in this pre-specified subanalysis all patients with at least 1 clinically relevant BMS or DES ISR treated with SES. Primary endpoint was major adverse cardiac events and stent thrombosis rate at 1 year. Of 15,147 patients enrolled, 1,590 (10.5{\%}) presented at least 1 ISR (BMS group, n = 1,235, DES group, n = 355). Patients with DES ISR had higher incidence of diabetes (39.4{\%} vs. 26.9{\%}, p <0.001), renal insufficiency (5.8{\%} vs. 2.3{\%}, p = 0.003), and prior coronary artery bypass graft (20.5{\%} vs. 11.8{\%}, p <0.001). At 1 year, death (1.4{\%} for BMS vs. 2.1{\%} for DES, p = 0.3) and myocardial infarction (2.4{\%} for BMS and 3.3{\%} for DES, p = 0.3) rates were similar, whereas ischemia-driven target lesion revascularization and definite/probable late stent thrombosis were higher in patients with DES ISR (6.9{\%} vs. 3.1{\%}, p = 0.003, and 1.8{\%} vs. 0.5{\%}, p = 0.04, respectively). Use of SES for either BMS or DES ISR treatment is safe and associated with low target lesion revascularization recurrence and no apparent safety concern.",
keywords = "in-stent restenosis, sirolimus-eluting stent(s), target lesion revascularization",
author = "Alexandre Abizaid and Costa, {J. Ribamar} and Adrian Banning and Bartorelli, {Antonio L.} and Vladimir Dzavik and Stephen Ellis and Runlin Gao and Holmes, {David R.} and Jeong, {Muyng Ho} and Victor Legrand and Neumann, {Franz Josef} and Maria Nyakern and Amy Orlick and Christian Spaulding and Stephen Worthley and Urban, {Philip M.}",
year = "2012",
month = "1",
doi = "10.1016/j.jcin.2011.09.016",
language = "English",
volume = "5",
pages = "64--71",
journal = "JACC: Cardiovascular Interventions",
issn = "1936-8798",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - The sirolimus-eluting cypher select coronary stent for the treatment of bare-metal and drug-eluting stent restenosis

T2 - Insights from the e-select 64-71 (multicenter post-market surveillance) registry

AU - Abizaid, Alexandre

AU - Costa, J. Ribamar

AU - Banning, Adrian

AU - Bartorelli, Antonio L.

AU - Dzavik, Vladimir

AU - Ellis, Stephen

AU - Gao, Runlin

AU - Holmes, David R.

AU - Jeong, Muyng Ho

AU - Legrand, Victor

AU - Neumann, Franz Josef

AU - Nyakern, Maria

AU - Orlick, Amy

AU - Spaulding, Christian

AU - Worthley, Stephen

AU - Urban, Philip M.

PY - 2012/1

Y1 - 2012/1

N2 - This study sought to compare the 1-year safety and efficacy of Cypher Select or Cypher Select Plus (Cordis Corporation, Bridgewater, New Jersey) sirolimus-eluting stents (SES) with the treatment of bare-metal stents (BMS) and drug-eluting stent (DES) in-stent restenosis (ISR) in nonselected, real-world patients. There is paucity of consistent data on DES for the treatment of ISR, especially, DES ISR. The e-SELECT (Multicenter Post-Market Surveillance) registry is a Web-based, multicenter and international registry encompassing virtually all subsets of patients and lesions treated with at least 1 SES during the period from 2006 to 2008. We enrolled in this pre-specified subanalysis all patients with at least 1 clinically relevant BMS or DES ISR treated with SES. Primary endpoint was major adverse cardiac events and stent thrombosis rate at 1 year. Of 15,147 patients enrolled, 1,590 (10.5%) presented at least 1 ISR (BMS group, n = 1,235, DES group, n = 355). Patients with DES ISR had higher incidence of diabetes (39.4% vs. 26.9%, p <0.001), renal insufficiency (5.8% vs. 2.3%, p = 0.003), and prior coronary artery bypass graft (20.5% vs. 11.8%, p <0.001). At 1 year, death (1.4% for BMS vs. 2.1% for DES, p = 0.3) and myocardial infarction (2.4% for BMS and 3.3% for DES, p = 0.3) rates were similar, whereas ischemia-driven target lesion revascularization and definite/probable late stent thrombosis were higher in patients with DES ISR (6.9% vs. 3.1%, p = 0.003, and 1.8% vs. 0.5%, p = 0.04, respectively). Use of SES for either BMS or DES ISR treatment is safe and associated with low target lesion revascularization recurrence and no apparent safety concern.

AB - This study sought to compare the 1-year safety and efficacy of Cypher Select or Cypher Select Plus (Cordis Corporation, Bridgewater, New Jersey) sirolimus-eluting stents (SES) with the treatment of bare-metal stents (BMS) and drug-eluting stent (DES) in-stent restenosis (ISR) in nonselected, real-world patients. There is paucity of consistent data on DES for the treatment of ISR, especially, DES ISR. The e-SELECT (Multicenter Post-Market Surveillance) registry is a Web-based, multicenter and international registry encompassing virtually all subsets of patients and lesions treated with at least 1 SES during the period from 2006 to 2008. We enrolled in this pre-specified subanalysis all patients with at least 1 clinically relevant BMS or DES ISR treated with SES. Primary endpoint was major adverse cardiac events and stent thrombosis rate at 1 year. Of 15,147 patients enrolled, 1,590 (10.5%) presented at least 1 ISR (BMS group, n = 1,235, DES group, n = 355). Patients with DES ISR had higher incidence of diabetes (39.4% vs. 26.9%, p <0.001), renal insufficiency (5.8% vs. 2.3%, p = 0.003), and prior coronary artery bypass graft (20.5% vs. 11.8%, p <0.001). At 1 year, death (1.4% for BMS vs. 2.1% for DES, p = 0.3) and myocardial infarction (2.4% for BMS and 3.3% for DES, p = 0.3) rates were similar, whereas ischemia-driven target lesion revascularization and definite/probable late stent thrombosis were higher in patients with DES ISR (6.9% vs. 3.1%, p = 0.003, and 1.8% vs. 0.5%, p = 0.04, respectively). Use of SES for either BMS or DES ISR treatment is safe and associated with low target lesion revascularization recurrence and no apparent safety concern.

KW - in-stent restenosis

KW - sirolimus-eluting stent(s)

KW - target lesion revascularization

UR - http://www.scopus.com/inward/record.url?scp=84855605315&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855605315&partnerID=8YFLogxK

U2 - 10.1016/j.jcin.2011.09.016

DO - 10.1016/j.jcin.2011.09.016

M3 - Article

VL - 5

SP - 64

EP - 71

JO - JACC: Cardiovascular Interventions

JF - JACC: Cardiovascular Interventions

SN - 1936-8798

IS - 1

ER -